Journal
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE
Volume 15, Issue -, Pages 1261-1276Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/JMDH.S251861
Keywords
generalized arterial calcification of infancy; ectonucleotide pyrophosphatase/phosphodiesterase 1; ATP binding cassette subfamily C member 6; vascular calcification
Categories
Funding
- Leducq Foundation Grant
- 4C Medical
- 4Tech
- Abbott Vascular
- Ablative Solutions
- Absorption Systems
- Advanced NanoTherapies
- Aerwave Medical
- Alivas
- Amgen
- Asahi Medical
- Aurios Medical
- Avantec Vascular
- BD
- Biosensors
- Biotronik
- Biotyx Medical
- Bolt Medical
- Boston Scientific
- Canon USA
- Cardiac Implants
- Cardiawave
- CardioMech
- Cardionomic
- Cerus EndoVascular
- Chansu Vascular Technologies
- Children's National Medical Center
- Concept Medical
- Cook Medical
- Cooper Health
- Coramaze Technologies GmbH
- CRL/AccelLab
- Croivalve
- CSI
- Dexcom
- Edwards Lifesciences
- Elucid Bioimaging
- eLum Technologies
- Emboline
- Endotronix
- Envision
- Filterlex
- Imperative Care
- Innovalve
- Innovative Cardiovascular Solutions
- Intact Vascular
- Interface Biologics
- Intershunt Technologies
- Invatin Technologies
- Lahav CRO
- Limflow
- LJ Biosciences
- Lutonix
- Lyra Therapeutics
- Mayo Clinic
- Maywell
- MD Start
- MedAlliance
- Medanex
- Medtronic
- Mercator
- Microport
- Microvention
- Neovasc
- Nephronyx
- Nova Vascular
- Nyra Medical
- Occultech
- Olympus
- Ohio Health
- OrbusNeich
- Ossio
- Phenox
- Pi-Cardia
- Polares Medical
- Polyvascular
- Profusa
- ProKidney LLC
- Protembis
- Pulse Biosciences
- Qool Therapeutics
- Recombinetics
- Recor Medical
- Regencor
- Renata Medical
- Restore Medical
- Ripple Therapeutics
- Rush University
- Sanofi
- Shockwave
- Sahajanand Medical Technologies
- SoundPipe
- Spartan Micro
- Spectrawave
- Surmodics
- Terumo Corporation
- Jacobs Institute
- Transmural Systems
- Transverse Medical
- TruLeaf Medical
- UCSF
- UPMC
- Vascudyne
- Vesper
- Vetex Medical
- Whiteswell
- WL Gore
- Xeltis
- Celonova
- [NIH-HL141425]
Ask authors/readers for more resources
It is rare to see evidence of arterial calcification in infants and children, and when detected, genetic disorders of calcium metabolism should be suspected. Generalized arterial calcification of infancy (GACI) is a hereditary disease characterized by severe arterial calcification, mostly involving the media with marked intimal proliferation and ectopic mineralization. ENPP1 and ABCC6 gene variants are associated with the disease, with higher mortality in subjects carrying ENPP1 variants. Overall mortality in individuals with GACI is high, and there is currently no ideal therapy, but gene-targeted treatments are being developed.
It is very unusual to see evidence of arterial calcification in infants and children, and when detected, genetic disorders of calcium metabolism should be suspected. Generalized arterial calcification of infancy (GACI) is a hereditary disease, which is characterized by severe arterial calcification of medium sized arteries, mostly involving the media with marked intimal proliferation and ectopic mineralization of the extravascular tissues. It is caused by inactivating variants in genes encoding either ENPP1, in a majority of cases (70-75%), or ABCC6, in a minority (9-10%). Despite similar histologic appearances between ENPP1 and ABCC6 deficiencies, including arterial calcification, organ calcification, and cardiovascular calcification, mortality is higher in subjects carrying the ENPP1 versus ABCC6 variants (40% vs 10%, respectively). Overall mortality in individuals with GACI is high (55%) before the age of 6 months, with 24.4% dying in utero or being stillborn. Rare cases show spontaneous regression with age, while others who survive into adulthood often manifest musculoskeletal complications (osteoarthritis and interosseous membrane ossification), enthesis mineralization, and cervical spine fusion. Despite recent advances in the understanding of the genetic mechanisms underlying this disease, there is still no ideal therapy for the resolution of vascular calcification in GACI. Although bisphosphonates with anti-calcification properties have been commonly used for the treatment of CAGE their benefit is controversial, with favorable results reported at one year and questionable benefit with delayed initiation of treatment. Enzyme replacement therapy with administration of recombinant form of ENPP1 prevents calcification and mortality, improves hypertension and cardiac function, and prevents intimal proliferation and osteomalacia in mouse models of ENPP1 deficiency. Therefore, newer treatments targeting genes are on the horizon. In this article, we review up to date knowledge of the understanding of GACI, its clinical, pathologic, and etiologic understanding and treatment in support of more comprehensive care of GACI patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available